Search

Now showing items 1-10 of 132

Stereotactic proton beam therapy for intracranial arteriovenous malformations

Vernimmen F.J.A.I.; Slabbert J.P.; Wilson J.A.; Fredericks S.; Melvill R. (2005)

Purpose: To investigate hypofractionated stereotactic proton therapy of predominantly large intracranial arteriovenous malformations (AVMs) by analyzing retrospectively the results from a cohort of patients. Methods and ...

Stereotactic proton beam therapy of skull base meningiomas

Vernimmen F.J.; Harris J.K.; Wilson J.A.; Melvill R.; Smit B.J.; Slabbert J.P. (2001)

Purpose: To review outcomes for patients with skull base meningiomas treated using the stereotactic proton beam at the National Accelerator Center (NAC), Republic of South Africa. Methods and Materials: Since 1993, 27 ...

Management of life-threatening haemoptysis in an area of high tuberculosis incidence

Gross A.M.; Diacon A.H.; Van Den Heuvel M.M.; Van Rensburg J.; Harris D.; Bolliger C.T. (2009)

BACKGROUND: Emergency admissions with life-threatening haemoptysis in an area of high tuberculosis (TB) incidence at the University of Stellenbosch and Tygerberg Academic Hospital, South Africa. It is unclear if lung ...

The diagnostic utility of adenosine deaminase isoenzymes in tuberculous pleural effusions

Zemlin A.E.; Burgess L.J.; Carstens M.E. (2009)

SETTING: Pleural adenosine deaminase (ADA) levels have been found to be useful in diagnosing tuberculous pleuritis. Elevated ADA levels have been attributed to ADA2 isoenzyme, although no comprehensive studies have evaluated ...

Cytokine production in patients with tuberculous pericarditis

Burgess L.J.; Reuter H.; Carstens M.E.; Taljaard J.J.F.; Doubell A.F. (2002)

SETTING: An academic hospital in the Western Cape, South Africa. OBJECTIVE: To evaluate cytokine production (interferon-gamma [IFN-γ], interleukin-1 [IL-1], interleukin-2 [IL-2], interleukin-6 [IL-6], interleukin-10 [IL-10], ...

Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures a prospective, controlled, randomized study of four hundred and fifty patients

Govender S.; Csimma C.; Genant H.K.; Valentin-Opran A.; Amit Y.; Arbel R.; Aro H.; Atar D.; Bishay M.; Borner M.G.; Chiron P.; Choong P.; Cinats J.; Courtenay B.; Feibel R.; Geulette B.; Govender S.; Gravel C.; Haas N.; Raschke M.; Hammacher E.; Van der Velde D.; Hardy P.; Holt M.; Josten C.; Ketterl R.L.; Lindeque B.; Lob G.; Mathevon H.; McCoy G.; Marsh D.; Miller R.; Munting E.; Oevre S.; Nordsletten L.; Patel A.; Pohl A.; Rennie W.; Reynders P.; Rommens P.M.; Rondia J.; Rossouw W.C.; Daneel P.J.; Ruff S.; Ruter A.; Santavirtal S.; Schidhauer T.A.; Gekle C.; Schnettler R.; Segal D.; Seiler H.; Snowdowne R.B.; Stapert J.; Taglang G.; Verdonik R.; Vogels L.; Weckbach A.; Wentzensen A.; Wisriewsk T. (2002)

Background: The treatment of open fractures of the tibial shaft is often complicated by delayed union and non-union. The objective of this study was to evaluate the safety and efficacy of the use of recombinant human bone ...

Traumatic dislocation of the atlanto-occipital joint

Govender S.; Vlok G.J.; Fisher-Jeffes N.; Du Preez C.P. (2003)

We present four patients who had sustained a traumatic dislocation of the atlanto-occipital joint. The diagnosis was initially missed in two patients. One patient, who was neurologically intact, was treated non-operatively. ...

Phase II trial of ZD0473 as second-line therapy in mesothelioma

Giaccone G.; O'Brien M.E.R.; Byrne M.J.; Bard M.; Kaukel E.; Smit B. (2002)

A phase II, open-label, non-comparative, multicentre trial of the platinum analogue ZD0473 as second-line therapy for pleural mesothelioma has been completed. The objectives were to evaluate the activity and tolerability ...

Esomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitis

Schneider, H.; Van Rensburg, C.; Schmidt, S.; Aboo, N.; Makela, H.; Naucler, E.; Hallerback, B.; Svedberg, L-E. (2004)

Background/Aims: An intravenous formulation of esomeprazole has been developed for use in patients where oral administration is not appropriate. This study evaluated safety after 1 and 4 weeks, and efficacy after 4 weeks' ...

An atropine and glycopyrrolate combination reduces mortality in organophosphate poisoning

Arendse R.; Irusen E. (2009)

Anticholinergics are the mainstay of the pharmacological management of organophosphate poisoning (OPP). Atropine has the potential to cause central toxicity which may complicate the management of this life-threatening ...

1
2
3
4
. . .
14